Nursing of autologous PSMA chimeric antigen receptor T cells for the treatment of castration-resistant prostate cancer

Objective: To examine the nursing care involved in autologous PSMA CAR-T cell therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: Nursing care was provided at three key stages: before blood sample collection, during chemotherapy pretreatment, and while reinfusing CAR-T cells. Adverse events, including cytokine release syndrome (CRS), nervous system toxicity, and abnormal coagulation function, were closely monitored. Results: Of the five patients, four showed improvement and were discharged. However, one patient with grade 4 CRS unfortunately died after discharge due to progressive disease and multiple organ failure. Conclusion: In conclusion, the new autologous PSMA CAR-T cell treatment regimen provides hope for patients with mCRPC. Nurses should be familiar with the treatment protocol and operational points, remain vigilant for potential adverse events during treatment, and implement timely interventions to enhance treatment efficacy and reduce the occurrence of adverse events.